rewrite this title Solid Biosciences Inc. (SLDB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Anupam RamaJPMorgan Chase & Co, Research Division

Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I am one of the senior biotech analysts here at JPMorgan.

I’m joined by my squad, Rati Pinge, Priyanka Grover, Joyce Zhou. Our next presenting company is Solid Biosciences. And presenting on behalf of the company, we have CEO, Bo Cumbo.

Alexander CumboPresident, CEO & Director

Yes. Thank you, Anupam. Thank you JPMorgan for the invitation. It’s good to see all the friendly faces in the audience today and those who are attending. Before I start, the forward-looking statements, I’ll give you — I’m going to pause on the forward-looking statements and tell you a little story.

Before we actually started the presentation, 2 of our attorneys come up to me and talk about, are you excited about JPMorgan?

And I’m like, “Oh, great. What are you going to say?” Well, I’m going to tell you about everything that’s going on. We’ve dosed 33 patients, all safe, no drug-induced liver injury, no myocarditis, no aHUS.

We’ve already enrolled our first patient and scheduled our first patient in the double-blind, placebo controlled. We dosed our first patient in FA. This has been — this is the best year that we’ve ever had as a company.

Our capsids — we’ve had 50 different agreements for our capsids. People are starting to come to us as a platform technology company and using all our delivery vehicles inside for a Solid inside for next-generation therapies.

We have